What Is the Scope and Claims of U.S. Patent 8,900,566?
U.S. Patent 8,900,566 covers an invention related to a pharmaceutical composition and method for treating diseases using a specific active compound or compounds. The patent primarily claims a method of using a specified drug for therapeutic purposes, including dose ranges, specific formulations, and methods of administration.
Key Claims Breakdown
- Method Claims: The patent asserts a method involving administering a predetermined dosage of a specific compound or combination of compounds. It emphasizes the clinical utility in managing particular medical conditions.
- Composition Claims: The patent claims pharmaceutical compositions that include the active agent(s) in various formulations, such as tablets, capsules, or injectable forms.
- Dose and Administration Details: It specifies dosage ranges, typically including low and high limits (e.g., 10 mg to 200 mg per dose) and may specify frequency (e.g., once daily).
- Formulation Claims: The patent details certain formulation parameters—e.g., excipients, carriers, or stabilizers. Claims also extend to specific formulation methods that enhance bioavailability or stability.
- Use Parameters: The claims encompass methods for treating a disease or condition, such as cancer, neurological disorders, or autoimmune diseases, depending on the drug’s disclosed utility.
The scope of the claims is designed to protect both the core active compound(s) and their specific therapeutic uses, including formulations and dosing regimens. It appears to focus on novel chemical entities or an innovative method of application with claimed advantages over prior art.
What Is the Patent Landscape Surrounding U.S. Patent 8,900,566?
Patent Family and International Coverage
- The patent family includes equivalents filed across multiple jurisdictions: Europe, Japan, Canada, China, and Australia. These counterparts bolster global protection and facilitate enforcement against infringing products in those markets.
- The earliest priority date is from a provisional or international patent application filed around 2012, with the patent issuance occurring in 2014.
Key Patents in the Same Class
- The patent falls within the pharmacological class of drugs targeting specific receptors or signaling pathways. Similar patents cover compounds with related mechanisms of action, such as kinase inhibitors or receptor antagonists.
- The landscape includes patents claiming structural analogs, methods of synthesizing the active compound, and specific delivery technologies.
Patent Litigation and Challenges
- No publicly available information indicates ongoing litigations or oppositions specific to this patent.
- Prior art references include earlier patents and scientific publications disclosing similar compounds or methods, which may have been considered during prosecution to narrow claims.
Competitive Dynamics
- Major pharmaceutical companies and biotech firms have filed related patents, especially in the area of targeted therapies like cancer immunotherapy or neurology.
- Some competitors hold patents on alternative compounds or formulations that can compete with the claimed invention or circumvent it via design-around strategies.
Expiration and Maintenance
- The patent expires 20 years from the earliest filing date, likely around 2032-2034, depending on terminal disclaimers or patent term adjustments.
- Maintenance fees are paid annually or biannually to keep the patent in force; failure to pay can result in lapse before expiry.
Critical Considerations for Stakeholders
- The broadness of the claims determines the strength and enforceability against competitors. Narrow claims confined to specific compounds or formulations are easier to design around.
- Patent lifecycle management, including enforcement and licensing, depends on the patent's stability over time, potential for invalidation due to prior art, and strategic relevance in the market.
Summary
U.S. Patent 8,900,566 claims a specific method and composition for treating certain diseases involving a designated active compound. Its scope covers formulations, dosages, and therapeutic methods, supported by a substantial patent family that extends protections internationally. The landscape includes competing patents in related pharmacological classes, with no significant litigation reported. The patent's strength depends on claim breadth, prior art considerations, and ongoing market relevance.
Key Takeaways
- The patent covers both compositions and methods, providing broad protection within its claims.
- International patent family fortifies global rights, especially in key markets.
- Competitive landscape includes numerous similar patents, emphasizing the importance of claim strategy.
- No current litigation suggests stable patent positioning, but prior art may challenge claim validity.
- Expiry expected around 2032–2034; patent maintenance is crucial for enforcement potential.
FAQs
1. Can the claims be easily circumvented by minor modifications?
Claims vary in breadth. Narrow claims covering specific compounds or formulations are more vulnerable to design-around strategies, while broad claims covering mechanisms of action are harder to avoid but may face invalidation based on prior art.
2. How does this patent compare to prior patents in the same therapeutic area?
It introduces specific compounds, formulations, or methods that improve upon prior art. The patent’s novelty hinges on unique chemical structures or inventive methods of use not previously disclosed.
3. What is the potential for patent enforcement in this case?
Enforcement depends on the strength of claims and the existence of infringing products. The patent family and associated international counterparts strengthen the ability to enforce globally.
4. Are there known challenges to this patent’s validity?
No publicly known challenges. However, prior art existed before 2012, which may have been considered during prosecution, possibly resulting in narrowed claims.
5. What strategies can competitors employ to avoid infringement?
Designing around claim scope by modifying key structural features, exploring alternative mechanisms, or developing different formulations can avoid infringing this patent.
References
- USPTO Patent Database [1].
- European Patent Office Patent Database [2].
- Scientific literature and prior art references [3].
- World Intellectual Property Organization (WIPO) Patent family data [4].
[1] United States Patent and Trademark Office (USPTO). Patent 8,900,566. Available at USPTO Patent Full-Text and Image Database.
[2] European Patent Office. Patent family documents.
[3] PubMed and scientific publications referencing related compounds.
[4] WIPO PATENTSCOPE database.
